Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice
Ibrutinib is a bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment of multiple B-cell malignancies, including chronic lymphocytic leukemia (CLL). In addition to blocking B-cell receptor signaling and chemokine receptor-mediated pathways in CLL cells, that are known drivers of diseas...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Ferrata Storti Foundation
2020-03-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/9685 |
| Tags: |
No Tags, Be the first to tag this record!
|